Phathom Q3 net loss $43.2M; VOQUEZNA FDA approved for Erosive GERD; Dec launch

Phathom Pharmaceuticals, Inc.

2023-Q3 EPS reported -$2.48

Net loss $43.2M in Q3 2023 vs $51.1M in Q3 2022; includes $6.1M stock-based compensation.
Cash $213.7M at Sep 30; $175M from revenue interest financing plus $100M Hercules loan available.
FDA approved VOQUEZNA (vonoprazan) for Erosive GERD in Nov 2023; launch expected Dec 2023.
NDA submitted for vonoprazan as daily Non-Erosive GERD treatment in Sep 2023; FDA action Q3 2024.
Phase 3 As Needed NERD trial to start in 2024; cash expected to fund ops through end of 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phathom Pharmaceuticals, Inc. reported the third quarter of 2023 results: net income $43.2 million.

Period: the third quarter of 2023
Net income: $43.2 million
Result: reported results

Exact text from the filing

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2023

View on SEC.gov

Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-274082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.